Research To Practice | Oncology Videos

Latest Episodes:

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of MET-Altered Non-Small Cell Lung Cancer Nov 07, 2022

Show notes

Featuring an interview with Dr Rebecca Heist, including the following topics:

Mechanism of action and toxicity of amivantamab in patients with MET-driven non-small cell lung cancer (NSCLC) (0:00)
Potential role of MET inhibitors as pantumor treatment for MET-altered cancer (2:27)
Selection and sequencing of targeted therapy for patients with MET-altered NSCLC (5:24)
Managing MET-altered NSCLC in patients with brain metastases (7:55)
Immune checkpoint inhibitors and MET-targeted therapy for patients with NSCLC and MET alterations (9:27)
Case: A woman in her mid 60s with no smoking history and newly diagnosed NSCLC with a MET exon 14 skipping mutation (14:55)
Case: A woman in her mid 70s with MET-amplified relapsed NSCLC with an EGFR L858R mutation (24:02)
Novel agents and strategies for the management of MET-altered NSCLC (32:00)

CME information and select publications

Myelofibrosis | Oncology Today with Dr Neil Love: Current Management of Myelofibrosis (Companion Faculty Lecture) Nov 03, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Brady Stein, including the following topics:

Introduction to myelofibrosis (MF) and the use of JAK inhibitors as therapy for MF (0:00)
Available efficacy and safety data with ruxolitinib for MF (4:17)
Pivotal data leading to the approval of fedratinib (13:11)
Unique features of pacritinib and current role in treatment algorithm for MF; other novel therapies under investigation (19:17)

CME information and select publications

Myelofibrosis | Oncology Today with Dr Neil Love: Current Management of Myelofibrosis Nov 03, 2022

Show notes

Featuring an interview with Dr Brady Stein, including the following topics:

Case: A man in his late 70s with myelofibrosis (MF) presenting with fatigue and night sweats (0:00)
Incidence and severity of fatigue and other symptoms; use of symptom scales to measure severity (3:43)
Rapidity of symptom response to ruxolitinib; emerging data with momelotinib (7:34)
Novel therapeutic targets for MF: BET, PI3K and BCL2 (13:25)
Available data on JAK inhibitors for essential thrombocytosis and polycythemia vera; pathogenesis of pruritus and optimal management (20:31)
Clinical pearls on managing splenomegaly, weight loss and other MF symptoms (26:34)
Risks of localized therapy for splenomegaly; splenic progression among patients receiving ruxolitinib (30:14)
Prevention and management of withdrawal rebound from ruxolitinib; factors to consider in choosing JAK inhibitors for different risk groups (34:17)
Myths and misperceptions about MF among community general oncologists (38:26)
Management algorithms for transplant-eligible and transplant-ineligible patients (44:32)
Current understanding of MF pathophysiology; end-of-life care for patients with MF (50:13)

CME information and select publications

Neuroendocrine Tumors | Oncology Today with Dr Neil Love: Neuroendocrine Tumors (Companion Faculty Lecture) Nov 01, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Pamela Kunz, including the following topics:

Epidemiology of neuroendocrine tumors (NETs) (0:00)
Strategies for the hormonal control of NETs (11:03)
Tools for tumor control (17:03)

CME information and select publications

Neuroendocrine Tumors | Oncology Today with Dr Neil Love: Neuroendocrine Tumors Nov 01, 2022

Show notes

Featuring an interview with Dr Pamela Kunz, including the following topics:

Increasing incidence of neuroendocrine tumors (NETs); heterogeneity in the clinical presentation of patients with NETs (0:00)
Case: A woman in her early 50s newly diagnosed with a metastatic NET; optimal patient workups (5:08)
Choosing between observation and treatment for metastatic NETs (9:52)
Cardiovascular issues associated with NETs; factors to consider when selecting a somatostatin analogue (14:16)
Case: A man in his early 60s with a 5-year history of metastatic small bowel NET; available data with telotristat for carcinoid syndrome diarrhea (21:13)
Case: A man in his early 60s with a 2-month history of lower left quadrant cramping, reduced appetite, and weight loss (28:07)
Key takeaways about the management of NETs; potential future strategies for treating NETs (33:26)

CME information and select publications

Non-Small Cell Lung Cancer | Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation — Part 3 Oct 31, 2022

Show notes

Featuring perspectives from Dr Pasi Jänne, including the following topics:

Introduction: Journal Club with Pasi A Jänne, MD, PhD — Part 1 (0:00)
Case: An Asian man in his late 60s with adenocarcinoma of the lung and pleural effusion with EGFR amplification (PD-L1 20%) — Jennifer L Dallas, MD (12:33)
Case: A man in his late 50s with metastatic adenocarcinoma of the lung with discordant EGFR testing results and a new mediastinal lesion after therapy with osimertinib — Rohit Gosain, MD (16:10)
Case: A man in his late 40s with metastatic adenocarcinoma of the lung and a brain metastasis with an EGFR exon 19 mutation and disease progression after stereotactic body radiation therapy (SBRT) and osimertinib, now with an ALK mutation by RNA testing (PD-L1 0) — Namrata I Peswani, MD (18:44)
Case: A man in his early 50s with Stage III unresectable adenocarcinoma of the lung with an EGFR mutation who receives chemoradiation therapy and consolidation durvalumab, now with metastatic recurrence — Ferdy Santiago, MD (21:51)
Case: A man in his early 70s with Stage IIIC large cell neuroendocrine carcinoma of the lung and an EGFR S768I mutation (PD-L1 1%) — Jarushka Naidoo, MB BCH, MHS (28:17)
Case: A man in his early 80s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion mutation and disease progression on mobocertinib — Jiaxin (Jason) Niu, MD, PhD (32:15)
Case: A woman in her mid 70s with adenocarcinoma of the lung and an EGFR exon 20 insertion mutation with new bone and brain metastases after therapy with osimertinib — Dr Niu (37:11)
Journal Club with Dr Jänne — Part 2 (43:02)
Case: A woman in her mid 80s with metastatic adenocarcinoma of the lung with an EGFR exon 21 mutation who switched to erlotinib due to osimertinib-related toxicities, now with recurrence at the primary site (PD-L1 10%) — John Yang, MD (55:18)
Case: An Asian man in his early 70s with metastatic adenocarcinoma of the lung with an EGFR exon 19 deletion and brain metastases who receives SBRT and osimertinib but develops extracranial biopsy-proven small cell lung cancer progression — Dr Niu (58:35)

CME information and select publications

Multiple Myeloma | Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 1 Oct 28, 2022

Show notes

Featuring perspectives from Dr Sagar Lonial, including the following topics:

Journal Club with Sagar Lonial, MD — Part 1 (0:00)
Case: A man in his late 50s with relapsed t(11;14) multiple myeloma (MM) 17 years after initial induction treatment and ASCT — Rajalaxmi McKenna, MD (16:45)
Case: A man in his mid 70s with NDMM receives daratumumab/lenalidomide/dexamethasone in EAA181 clinical trial and develops ileus — Erik Rupard, MD (31:09)
Case: A man in his early 80s with NDMM, a borderline performance status and multiple medical comorbidities, including DM, CHF and CKD — Ranju Gupta, MD (35:18)
Case: A woman in her late 60s with biochemical progression of del(17p) MM, s/p RVd, ASCT and 1 year of maintenance bortezomib/lenalidomide — Warren S Brenner, MD (38:40)
Case: An otherwise healthy man in his mid 70s with refractory MM, s/p 5 prior lines of therapy — Jeremy Lorber, MD (43:36)
Faculty Survey (55:05)

CME information and select publications

Melanoma | Oncology Today with Dr Neil Love: BRAF-Mutant Metastatic Melanoma (Companion Faculty Lecture) Oct 27, 2022

Show notes

Featuring a slide presentation and related discussion from Prof Axel Hauschild, including the following topics:

Emerging data with targeted agents for metastatic melanoma (0:00)
Current and future roles for immune checkpoint inhibitors in therapy for melanoma (11:13)
Comparing targeted agents and immune checkpoint inhibitors (17:34)
Current melanoma guidelines and other therapies under investigation (24:09)

CME information and select publications

Melanoma | Oncology Today with Dr Neil Love: BRAF-Mutant Metastatic Melanoma Oct 27, 2022

Show notes

Featuring an interview with Prof Axel Hauschild, including the following topics:

Pan-tumor approval of dabrafenib/trametinib; data with adjuvant targeted therapy for melanoma (0:00)
Emerging data with encorafenib/binimetinib for Stage II melanoma; switching from dabrafenib/trametinib to encorafenib/binimetinib (5:23)
Recent data with ipilimumab/nivolumab versus dabrafenib/trametinib from the DREAMseq trial; using targeted therapy after immunotherapy (9:58)
Relationship between tumor mutational burden and response to targeted therapies and immunotherapies; PD-L1 expression and efficacy of immunotherapy alone compared to in combination (15:36)
T-cell targets for immunoregulatory antibody therapy; treatment for patients with underlying autoimmune disease (20:23)
Influence of corticosteroids on immunotherapy efficacy; adverse event profiles of dabrafenib/trametinib and encorafenib/binimetinib and optimal management (25:13)
Case: A man in his early 50s with an ulcerated melanoma metastasis and BRAF mutation (32:05)
Case: A woman in her early 40s with BRAF-mutated melanoma and a poor ECOG performance status (41:25)

CME information and select publications

Diffuse Large B-Cell Lymphoma | Challenging Cases from the Community: Investigators Provide Perspectives on the Optimal Management of Diffuse Large B-Cell Lymphoma Oct 26, 2022

Show notes

Featuring perspectives from Drs Jeremy Abramson, Sonali Smith and Jason Westin, including the following topics: